Floatz logo

Technetate(3-)-99Tc, (N-(4-(((2-Amino-1,4-Dihydro-4-Oxo-6-Pteridinyl)Methyl)Amino)Benzoyl)-D-.Gamma.-Glutamyl-(2S)-2-(Amino-.Kappa.N)-.Beta.-Alanyl-L-.Alpha.-Aspartyl-.Kappa.N-L-Cysteinato(6-)-.Kappa.N,.Kappa.S)Oxo-, Hydrogen (1:3), (Sp-5-24)-

Osteoarthritis

Mayo ClinicSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

15 Active assets in the Osteoarthritis cohort.

Asset / SponsorPhaseRating
Naltrexone
Brigham and Women's Hospital
Phase 4BBB
Buprenorphine
Mundipharma Pte Ltd.
Phase 4BBB
Oxycodone
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 4BBB
Fentanyl
Janssen Pharmaceutica
Phase 4BBB
Duloxetine
The Catholic University of Korea
Phase 4BBB

View all 47 →

Same molecule, other indications

Technetate(3-)-99Tc, (N-(4-(((2-Amino-1,4-Dihydro-4-Oxo-6-Pteridinyl)Methyl)Amino)Benzoyl)-D-.Gamma.-Glutamyl-(2S)-2-(Amino-.Kappa.N)-.Beta.-Alanyl-L-.Alpha.-Aspartyl-.Kappa.N-L-Cysteinato(6-)-.Kappa.N,.Kappa.S)Oxo-, Hydrogen (1:3), (Sp-5-24)- is also rated in:

rheumatoid arthritisDormant
B
Indicative · Phase 2
57 / 100
View asset →
Crohn diseaseDormant
B
Indicative · Phase 2
57 / 100
View asset →
systemic lupus erythematosusDormant
B
Indicative · Phase 2
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →